Patents by Inventor Didier Roche

Didier Roche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8183265
    Abstract: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: May 22, 2012
    Assignee: Merck Patent GmbH
    Inventors: Didier Roche, Denis Carniato, Liliane Doare, Christine Charon, Caroline Leriche
  • Publication number: 20110172265
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: August 5, 2009
    Publication date: July 14, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Febien Schmidlin
  • Publication number: 20110105475
    Abstract: The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
    Type: Application
    Filed: March 30, 2009
    Publication date: May 5, 2011
    Applicant: MERXCK PATENT GESELLSCHAFT
    Inventors: Didier Roche, Giséle Mautino, Ingo Kober, Francis Contard, Serge Christmann-Franck, Saumitra Sengupta, Ramesh Sistla, Gummadi Venkateshwar Rao
  • Publication number: 20110060007
    Abstract: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: April 8, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftling
    Inventors: Caroline Leriche, Denis Carniato, Didier Roche, Christine Charon, Liliane Doare
  • Publication number: 20100267761
    Abstract: The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: October 1, 2008
    Publication date: October 21, 2010
    Inventors: Denis Carniato, Didier Roche, Sophie Hallakou-Bozec, Melanie Schultz
  • Patent number: 7754740
    Abstract: Compounds of the formula (1): in which A, R1, R2 and R3 are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 17, 2005
    Date of Patent: July 13, 2010
    Assignee: Merck Patent GmbH
    Inventors: Nathalie Adje, Didier Roche, Stéphane Yvon
  • Publication number: 20100069365
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: October 5, 2007
    Publication date: March 18, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Publication number: 20100022597
    Abstract: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: November 22, 2007
    Publication date: January 28, 2010
    Inventors: Didier Roche, Denis Carniato, Liliane Doare, Christine Charon, Caroline Leriche
  • Publication number: 20090227631
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: November 22, 2006
    Publication date: September 10, 2009
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Patent number: 7582656
    Abstract: Compounds of the formula (I): in which the radicals R and R1 to R10 are as defined in the description, processes for the preparation of them, use thereof for the treatment of cardiovascular diseases, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: September 1, 2009
    Assignee: Merck Patent Gesellschaft
    Inventors: Didier Roche, Bruno Roux, Isabelle Berard
  • Patent number: 7482484
    Abstract: Disclosed are Compounds of formula I And methods of use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: January 27, 2009
    Assignee: Merck Patent GmbH
    Inventors: Nathalie Adje, Michel Brunet, Didier Roche, Jean-Jacques Zeiller, Stéphane Yvon, Valérie Guyard-Dangremont, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
  • Publication number: 20080114034
    Abstract: Compounds of the formula (1): in which A, R1, R2 and R3 are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 17, 2005
    Publication date: May 15, 2008
    Inventors: Nathalie Adje, Didier Roche, Stephane Yvon
  • Publication number: 20080004315
    Abstract: Compounds of the formula (I): in which the radicals R and R1 to R10 are as defined in the description, processes for the preparation of them, use thereof for the treatment of cardiovascular diseases, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 3, 2008
    Inventors: Didier Roche, Bruno Roux, Isabelle Berard
  • Publication number: 20060111445
    Abstract: The present invention relates to a compound of the formula ((I): in which: n is an integer chosen from 1, 2 and 3; Y represents O; N—OR9, in which R9 represents H or a saturated hydrocarbon-based aliphatic group; CR10R11, in which R10 and R11, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group; R1 and R2, which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R1 and R2 together form an optionally substituted saturated aliphatic hydrocarbon-based chain; the radicals R3 and R4, which may be identical or different, take any of the is meanings given above for R1 and R2, or alternatively R1 and the group R4 borne by the carbon alpha to CR1R2 represent nothing and a double bond links the CR1R2 carbon to the alpha CR3R4 carbon; or alternatively one of the radicals R1 and R2 forms with one of the radicals R3 and R4 an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain; one of the
    Type: Application
    Filed: December 16, 2003
    Publication date: May 25, 2006
    Inventors: Nathalie Adje, Michel Brunet, Didier Roche, Jean-Jacques Zeiller, Stephane Yvon, Valerie Guyard-Dangremont, Francis Contard, Daniel Guerrier, Gerard Ferrand
  • Publication number: 20060052588
    Abstract: The present invention relates to a novel nitrosation polymer of the formula in which X, Y, R1, R2 and R3 are as defined in claim 1. The invention also relates to a process for the preparation of the said polymer.
    Type: Application
    Filed: September 6, 2003
    Publication date: March 9, 2006
    Inventors: Didier Roche, Claude Lardy
  • Publication number: 20050020651
    Abstract: The present invention relates to a compound of the formula I: (Formula I) in which: A, B, R1, Z, n and R2 are as defined in claim 1. These compounds are useful in the treatment of dyslipidaemia, atherosclerosis and diabetes.
    Type: Application
    Filed: July 3, 2002
    Publication date: January 27, 2005
    Inventors: Didier Roche, Jean-Jacques Zeiller, Francis Contard, Valerie Guyard-Dangremont, Daniel Guerrier, Herve Dupont, Jean-Jacques Berthelon
  • Patent number: 6399599
    Abstract: Compounds of formula I wherein n is 1, 2 or 3; R1 is H, C1-4alkyl, aryl, or aryl-C1-4alkyl; Y is C1-4alkylene, —CO—C1-4alkylene, —CO—C2-5alkenylene, —CO—NH—, —CO—C1-3alkylene-NH—, or —CO—O—; R2 is an aromatic or heteroaromatic residue, each being optionally substituted by CF3, halogen, OH, C1-4alkoxy, amino, mono- or di-C1-4alkyl substituted amino, phenyl, benzyl or C1-4alkyl optionally substituted by amino; R3is the side chain present on the C&agr; of an &agr;-amino acid; R4 is biphenylyl, benzyl, hydroxy-benzyl, &agr;- or &bgr;-naphthyl-methyl, 5,6,7,8-tetrahydro-&bgr;-naphthyl-methyl or indolyl-methyl, each being optionally substituted on the ring by CF3, halogen, OH, C1-4alkoxy, amino, mono- or di-C1-4alkyl substituted amino, phenyl, benzyl or C1-4alkyl optionally substituted by amino; and X is —CN, —NR5R6 or —O—R8 wherein R5 is H, C1-6alkyl, aryl or aryl-C1-4alkyl; R6 is H or C1-6alkyl;
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Novartis AG
    Inventors: Rainer Albert, Josef G. Meingassner, Sompong Wattanasin, Gabriele Weitz-Schmidt, Karl Welzenbach, Ulrich Hommel, Claus Ehrhardt, Didier Roche, Joerg Kallen